中国药理学通报2018，Vol.34Issue(9)：1185-1189,5.DOI:10.3969/j.issn.1001-1978.2018.09.001
单抗诱发性细胞因子释放综合征和体外细胞因子释放实验的研究进展
Research development of cytokine release syndrome induced by monoclonal antibody and cytokine release assays in vitro
摘要
Abstract
Cytokine-release syndrome (CRS) triggered by mon-oclonal antibodies ( mAbs) is characterized by rapid onset and severe damage, and difficulty in prediction and control. Recent years,it has been a research focus on establishing a reliable ani-mal model in vivo and cytokine release assay( CRA) in vitro to predict CRS for preclinical safety evaluation. In this paper we summarize matters related to CRA applicable objects, considera-tions of method design and method optimization, aiming to pro-vide suggestions for the optimization of CRA prediction platform.关键词
单克隆抗体/细胞因子释放综合征/TGN1412/体外细胞因子释放实验/最低预期生物效应剂量/临床前安全性研究Key words
monoclonal antibody/cytokine-release syndrome/TGN1412/cytokine release assay in vitro/minimum anticipated biological effect level/preclinical safety study分类
医药卫生引用本文复制引用
尉骁璐,孙建华,宫丽崑..单抗诱发性细胞因子释放综合征和体外细胞因子释放实验的研究进展[J].中国药理学通报,2018,34(9):1185-1189,5.基金项目
国家科技部"重大新药创制"科技重大专项( No 2015ZX09501007,2017ZX09302008 -013) （ No 2015ZX09501007,2017ZX09302008 -013）
中科院药物所创新研究院自主部署项目(No. CASIMM0120163004) （No. CASIMM0120163004）
